A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?

[1]  J. Briones,et al.  Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma , 2020, Cancer medicine.

[2]  D. Maloney,et al.  Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. , 2020, Blood advances.

[3]  P. Riedell,et al.  A Multicenter Retrospective Analysis of Outcomes and Toxicities with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas , 2020 .

[4]  S. Jaglowski,et al.  CAR T-Cell Therapy: Clinical Outcomes, Patient Selection and Financial Metrics with Tisagenlecleucel and Axicabtagene Ciloleucel, a Single Center Experience , 2020 .

[5]  M. Perales,et al.  Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. , 2020, Blood advances.

[6]  Xavier Paoletti,et al.  From single-arm studies to externally controlled studies. Methodological considerations and guidelines. , 2019, Therapie.

[7]  D. Porter,et al.  A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy , 2019, Blood.

[8]  Michael L. Wang,et al.  Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma , 2019, Blood.

[9]  P. Riedell,et al.  A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas , 2019, Blood.

[10]  S. Nikiforow,et al.  Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US) , 2019, Blood.

[11]  A. Gajra,et al.  Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel , 2019, Blood.

[12]  J. Radford,et al.  Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England , 2019, Blood.

[13]  J. Vose,et al.  Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium , 2019, Blood.

[14]  Michael L. Wang,et al.  Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma , 2019, Blood.

[15]  R. Chawla,et al.  Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry , 2019, Blood.

[16]  M. Kersten,et al.  Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel , 2019, Blood.

[17]  L. Vercellino,et al.  Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience , 2019, Blood.

[18]  F. Locke,et al.  PCN445 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL) , 2019, Value in Health.

[19]  K. Batt,et al.  The potential impact of CAR T-cell treatment delays on society. , 2019, The American journal of managed care.

[20]  R. Houot,et al.  REAL‐WORLD RESULTS ON CD19 CAR T‐CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM , 2019, Hematological Oncology.

[21]  R. Houot,et al.  S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM , 2019, HemaSphere.

[22]  R. Pazdur,et al.  Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: A systematic analysis by the United States Food and Drug Administration (FDA). , 2019, Journal of Clinical Oncology.

[23]  J. Chavez,et al.  CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products , 2019, Therapeutic advances in hematology.

[24]  E. Sala,et al.  Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel , 2019, Cancer management and research.

[25]  Juliet Investigators.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2019 .

[26]  I. Flinn,et al.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.

[27]  D. Maloney,et al.  Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study , 2018, Blood.

[28]  M. Shadman,et al.  Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. , 2018, Blood.

[29]  A. Quintás-Cardama,et al.  CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma , 2018, Oncotarget.

[30]  Androulla N. Miliotou,et al.  CAR T-cell Therapy: A New Era in Cancer Immunotherapy. , 2018, Current pharmaceutical biotechnology.

[31]  J. Cerhan,et al.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.

[32]  David Madigan,et al.  Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making , 2017, Pharmacoepidemiology and drug safety.

[33]  Sofia Dias,et al.  Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  N. Schmitz,et al.  Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study , 2017, Bone Marrow Transplantation.

[35]  S. Palmer,et al.  Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison , 2016, Advances in Therapy.

[36]  Nicky J Welton,et al.  NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE , 2016 .

[37]  B. Coiffier,et al.  Diffuse large B-cell lymphoma: R-CHOP failure-what to do? , 2016, Hematology. American Society of Hematology. Education Program.

[38]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[39]  S. Palmer,et al.  Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma , 2016, Advances in Therapy.

[40]  Corinna Kiefer,et al.  Indirect Comparisons and Network Meta-Analyses. , 2015, Deutsches Arzteblatt international.

[41]  S Langham,et al.  The Challenges of Carrying out an Indirect Comparison with Single-Arm Studies. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[42]  Irina Proskorovsky,et al.  Simulation and Matching-Based Approaches for Indirect Comparison of Treatments , 2015, PharmacoEconomics.

[43]  Albrecht Reichle,et al.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  K. Chalkidou.  About the National Institute for Health and Care Excellence - NICE. , 2013, Acta medica portuguesa.

[45]  M Ladetto,et al.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[47]  R. Larson,et al.  Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. , 2007, Blood.

[48]  W. Gaus.  Anmerkungen zum Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) , 2006 .

[49]  R. Arceci,et al.  Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[51]  M. Gillick,et al.  Choosing appropriate medical care for the elderly. , 2001, Journal of the American Medical Directors Association.

[52]  S D Walter,et al.  The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.

[53]  J. Abramson.  Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. , 2019, Transfusion medicine reviews.

[54]  S. Schuster.  CD19-directed CAR T cells gain traction. , 2019, The Lancet. Oncology.

[55]  Richard Grieve,et al.  THE USE OF REAL WORLD DATA FOR THE ESTIMATION OF TREATMENT EFFECTS IN NICE DECISION MAKING , 2016 .

[56]  N. Schmitz,et al.  Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study , 2016, Bone Marrow Transplantation.

[57]  K. Jack Ishak,et al.  No Head-to-Head Trial? Simulate the Missing Arms , 2012, PharmacoEconomics.

[58]  Eric Q. Wu,et al.  Comparative Effectiveness Without Head-to-Head Trials , 2012, PharmacoEconomics.

[59]  M. Millman.  Committee on Monitoring Access to Personal Health Care Services , 1993 .